Avanos Medical Inc expected to post earnings of 21 cents a share - Earnings Preview

Avanos Medical

30/04/2024 16:44

* Avanos Medical Inc  AVNS.N   AVNS.K  is expected to show a
fall
in quarterly revenue when it reports  results on May 2 for the
period ending March 31 2024
    * The Alpharetta Georgia-based  company is expected to
report a
15.0% decrease in revenue to $162.9 million from $191.7 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Avanos Medical Inc is
for
earnings of 21 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 5.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Avanos
Medical
Inc is $23.50​, above​ its last closing price of $18.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   0.37        0.37       0.32      Missed  -12.7
 Sep. 30 0001  0.28        0.28       0.42      Beat    50
 Jan. 1 0001   0.28        0.30       0.37      Beat    24.2​
 Mar. 31 2023  0.27        0.27       0.27      Met     -1.5
 ​​Dec.        0.49        0.49       0.60      Beat    22.4
 31 2022                                                
 Sep. 30 2022  0.35        0.35       0.38      Beat    7.8​
 Jan. 1 0001   0.38        0.38       0.41      Beat    7.3
 Jan. 1 0001   0.26        0.26       0.26      Met     0
 This summary was machine generated April 30 at 15:44 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)